Search

MEM 1414

MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

Cinacalcet

It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Brasofensine

Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

99mTc-glucarate

99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.

Rivanicline

It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.

Omiganan

Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.

ALT-2074

An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

Amelubant

R1204

It is developed for the treatment of depression.

Dicyclomine

Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome. Thou...